Evidence map›Paper›PMID 35493449›Full record

ArticleFrontiers in immunology2022

Research Trends and Most Influential Clinical Studies on Anti-PD1/PDL1 Immunotherapy for Cancers: A Bibliometric Analysis.

Yanhao Liu, Yan Xu, Xi Cheng, Yaru Lin, Shu Jiang, Haiming Yu, Zhen Zhang, Linlin Lu, Xiaotao Zhang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 4 pooled it
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 4 syntheses or guidelines pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Yanhao LiuDepartment of Radiation Oncology, The Affiliated Qingdao Central Hospital of Qingdao University, Qingdao, China.
Yan XuDepartment of Radiation Oncology, The Affiliated Qingdao Central Hospital of Qingdao University, Qingdao, China.
Xi ChengDepartment of Radiation Oncology, The Affiliated Qingdao Central Hospital of Qingdao University, Qingdao, China.
Yaru LinDepartment of Radiation Oncology, The Affiliated Qingdao Central Hospital of Qingdao University, Qingdao, China.
Shu JiangDepartment of Radiation Oncology, The Affiliated Qingdao Central Hospital of Qingdao University, Qingdao, China.
Haiming YuDepartment of Radiation Oncology, The Affiliated Qingdao Central Hospital of Qingdao University, Qingdao, China.
Zhen ZhangDepartment of Radiation Oncology, The Affiliated Qingdao Central Hospital of Qingdao University, Qingdao, China.
Linlin LuDepartment of Radiation Oncology, The Affiliated Qingdao Central Hospital of Qingdao University, Qingdao, China.
Xiaotao ZhangDepartment of Radiation Oncology, The Affiliated Qingdao Central Hospital of Qingdao University, Qingdao, China.
Qingdao University · CNAffiliated Hospital of Qingdao University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this study, a bibliometric analysis was carried out to identify the most influential clinical studies and research trends on anti-programmed cell death 1/programmed cell death 1 ligand 1 (anti-PD1/PDL1) immunotherapy. On January 1, 2022, we used Web of Science to identify the 100 most frequently cited papers on clinical studies investigating anti-PD1/PDL1 immunotherapy, and extracted the following data: publication year, source title, country/region, institution, and the total number of citations. The research design and area were classified independently by the authors. Subsequently, we carried out a bibliometric analysis to determine the trends and identify the major journals on anti-PD1/PDL1 immunotherapy. The authors analyzed the current research hotspots based on papers published in major journals from 2020 to 2021. These 100 papers were cited a total of 138,840 times, and the median number of citations was 899.5 (range: 341-7,983). "Safety, activity, and immune correlates of anti-PD-1 antibody in cancer" by Topalian et al. had the highest number of citations (7,983 times).

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsMelanomaBibliometricsHumansImmunotherapybibliometric analysisclinical trialsimmunotherapylung cancermelanomaPD1/PDL1tumor mutation burden

Identifiers

PMID35493449
PMCPMC9044908
OpenAlexW4223561391

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.